Anavex Life Sciences Corp (AVXL)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $86.53M
Last updated: Nov 17, 2026 at 11:04 AM ET
Anavex Life Sciences Corp (AVXL) Earnings: Report Dates and Results
Anavex Life Sciences (AVXL) is expected to report earnings on Nov 23, 2026. In the quarter ended Jun 30, 2026, Anavex Life Sciences reported EPS of $0.08, above the -$0.08 estimate. It beat the EPS estimate in 6 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
AVXL has an expected report date of Nov 23, 2026.
AVXL Earnings Call
The latest AVXL earnings call transcript on file is labeled 2026Q1.
Read the 2026Q1 transcriptEarnings History
Of the 39 quarters below that had an estimate, AVXL beat 23, missed 10 and matched 6. The widest gap in the table came in the quarter ended Jun 30, 2026, when EPS landed 200.00% above the estimate.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported |
|---|---|---|---|---|---|---|---|---|---|
| Jun 30, 2026 | $0.08 | -$0.08 | -$0.08 - -$0.08 | +200.00% | Beat | N/A | 1 | 2 up, 0 down | Jul 30, 2026 |
| Mar 31, 2026 | -$0.13 | -$0.07 | -$0.07 - -$0.07 | -85.71% | Miss | N/A | 1 | 2 up, 0 down | Jun 23, 2026 |
| Dec 31, 2025 | -$0.06 | -$0.11 | -$0.12 - -$0.10 | +45.45% | Beat | N/A | 2 | 1 up, 0 down | Feb 9, 2026 |
| Sep 30, 2025 | -$0.11 | -$0.14 | -$0.16 - -$0.13 | +22.86% | Beat | N/A | 3 | 1 up, 1 down | Nov 25, 2025 |
| Jun 30, 2025 | -$0.16 | -$0.14 | -$0.16 - -$0.13 | -14.29% | Miss | N/A | 2 | 1 up, 0 down | Aug 12, 2025 |
| Mar 31, 2025 | -$0.13 | -$0.15 | -$0.16 - -$0.14 | +13.33% | Beat | N/A | 2 | 1 up, 0 down | May 13, 2025 |
| Dec 31, 2024 | -$0.14 | -$0.17 | -$0.17 - -$0.17 | +17.65% | Beat | N/A | 1 | 1 up, 0 down | Feb 12, 2025 |
| Sep 30, 2024 | -$0.14 | -$0.17 | -$0.17 - -$0.17 | +17.65% | Beat | N/A | 2 | 1 up, 0 down | Dec 23, 2024 |
| Jun 30, 2024 | -$0.14 | -$0.18 | -$0.21 - -$0.12 | +22.22% | Beat | N/A | 3 | 0 up, 0 down | Aug 6, 2024 |
| Mar 31, 2024 | -$0.13 | -$0.13 | -$0.13 - -$0.09 | 0.00% | In line | N/A | 2 | 0 up, 0 down | May 9, 2024 |
| Dec 31, 2023 | -$0.11 | -$0.15 | -$0.15 - -$0.14 | +26.67% | Beat | N/A | 2 | 0 up, 0 down | Feb 7, 2024 |
| Sep 30, 2023 | -$0.12 | -$0.15 | -$0.16 - -$0.13 | +20.00% | Beat | N/A | 3 | 0 up, 0 down | Nov 27, 2023 |
| Jun 30, 2023 | -$0.14 | -$0.17 | -$0.17 - -$0.16 | +17.65% | Beat | N/A | 3 | 0 up, 0 down | Aug 8, 2023 |
| Mar 31, 2023 | -$0.17 | -$0.18 | -$0.20 - -$0.18 | +5.56% | Beat | N/A | 3 | 0 up, 0 down | May 9, 2023 |
| Dec 31, 2022 | -$0.17 | -$0.19 | -$0.20 - -$0.18 | +10.53% | Beat | N/A | 3 | 0 up, 0 down | Feb 7, 2023 |
| Sep 30, 2022 | -$0.18 | -$0.16 | -$0.17 - -$0.15 | -12.50% | Miss | N/A | 5 | 0 up, 0 down | Nov 28, 2022 |
| Jun 30, 2022 | -$0.16 | -$0.16 | N/A | 0.00% | In line | N/A | N/A | 0 up, 0 down | Aug 9, 2022 |
| Mar 31, 2022 | -$0.14 | -$0.17 | -$0.18 - -$0.16 | +17.65% | Beat | N/A | 4 | 0 up, 0 down | May 10, 2022 |
| Dec 31, 2021 | -$0.14 | -$0.16 | -$0.16 - -$0.14 | +12.50% | Beat | N/A | 4 | 0 up, 0 down | Feb 9, 2022 |
| Sep 30, 2021 | -$0.15 | -$0.14 | -$0.17 - -$0.13 | -7.14% | Miss | N/A | 4 | 0 up, 0 down | Nov 24, 2021 |
| Jun 30, 2021 | -$0.14 | -$0.14 | -$0.15 - -$0.12 | 0.00% | In line | N/A | 5 | N/A | Aug 12, 2021 |
| Mar 31, 2021 | -$0.12 | -$0.15 | -$0.15 - -$0.12 | +20.00% | Beat | N/A | 4 | N/A | May 13, 2021 |
| Dec 31, 2020 | -$0.12 | -$0.12 | N/A | 0.00% | In line | N/A | 2 | N/A | Feb 11, 2021 |
| Sep 30, 2020 | -$0.10 | -$0.13 | -$0.14 - -$0.12 | +23.08% | Beat | N/A | 4 | N/A | Dec 28, 2020 |
| Jun 30, 2020 | -$0.11 | -$0.13 | -$0.14 - -$0.13 | +15.38% | Beat | N/A | 4 | N/A | Aug 6, 2020 |
| Mar 31, 2020 | -$0.12 | -$0.16 | -$0.20 - -$0.13 | +25.00% | Beat | N/A | 4 | N/A | May 7, 2020 |
| Dec 31, 2019 | -$0.12 | -$0.12 | -$0.16 - -$0.12 | 0.00% | In line | N/A | 2 | N/A | Feb 6, 2020 |
| Sep 30, 2019 | -$0.07 | -$0.15 | -$0.15 - -$0.15 | +53.33% | Beat | N/A | 2 | N/A | Dec 16, 2019 |
| Jun 30, 2019 | -$0.14 | -$0.17 | -$0.18 - -$0.16 | +17.65% | Beat | N/A | 2 | N/A | Aug 7, 2019 |
| Mar 31, 2019 | -$0.17 | -$0.14 | -$0.14 - -$0.14 | -21.43% | Miss | N/A | 1 | N/A | May 8, 2019 |
| Dec 31, 2018 | -$0.16 | -$0.13 | -$0.13 - -$0.13 | -23.08% | Miss | N/A | 1 | N/A | Feb 7, 2019 |
| Sep 30, 2018 | -$0.13 | -$0.11 | N/A | -18.18% | Miss | N/A | N/A | N/A | Dec 12, 2018 |
| Jun 30, 2018 | -$0.06 | -$0.10 | -$0.12 - -$0.09 | +40.00% | Beat | N/A | 3 | N/A | Aug 9, 2018 |
| Mar 31, 2018 | -$0.11 | -$0.10 | -$0.10 - -$0.10 | -10.00% | Miss | N/A | 2 | N/A | May 10, 2018 |
| Dec 31, 2017 | -$0.09 | -$0.08 | N/A | -12.50% | Miss | N/A | N/A | N/A | Feb 7, 2018 |
| Sep 30, 2017 | -$0.12 | -$0.10 | -$0.10 - -$0.10 | -20.00% | Miss | N/A | 2 | N/A | Dec 11, 2017 |
| Jun 30, 2017 | -$0.09 | -$0.09 | -$0.09 - -$0.09 | 0.00% | In line | N/A | 1 | N/A | Aug 7, 2017 |
| Mar 31, 2017 | -$0.04 | -$0.09 | N/A | +55.56% | Beat | N/A | N/A | N/A | May 10, 2017 |
| Dec 31, 2016 | -$0.08 | -$0.11 | N/A | +27.27% | Beat | N/A | N/A | N/A | Feb 7, 2017 |
| Sep 30, 2016 | -$0.18 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Dec 12, 2016 |
Annual EPS
EPS for the fiscal year ended Sep 30, 2026 was -$0.11, after -$0.54 the year before. It was -$0.33 for the year ended Sep 30, 2017, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Sep 30, 2026 | -$0.11 | N/A |
| Sep 30, 2025 | -$0.54 | N/A |
| Sep 30, 2024 | -$0.52 | N/A |
| Sep 30, 2023 | -$0.60 | N/A |
| Sep 30, 2022 | -$0.62 | N/A |
| Sep 30, 2021 | -$0.53 | N/A |
| Sep 30, 2020 | -$0.45 | N/A |
| Sep 30, 2019 | -$0.54 | N/A |
| Sep 30, 2018 | -$0.39 | N/A |
| Sep 30, 2017 | -$0.33 | N/A |
Earnings Calls
The 7 most recent earnings calls are listed below; the latest, 2026Q1 for the period ended Mar 31, 2026, runs about 3,800 words across 6 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q1 | Mar 31, 2026 | 3,817 | 6 | |
| 2025Q4 | Dec 31, 2025 | 4,299 | 6 | |
| 2025Q3 | Sep 30, 2025 | 2,527 | 5 | |
| 2025Q2 | Jun 30, 2025 | 2,660 | 5 | |
| 2025Q1 | Mar 31, 2025 | 2,570 | 4 | |
| 2024Q4 | Dec 31, 2024 | 1,193 | 3 | |
| 2024Q2 | Jun 30, 2024 | 2,776 | 5 |
2026Q1 Earnings Call
Opening remarks
Clint Tomlinson Host Good morning, everyone. And welcome to the Anavex Life Sciences Corp. fiscal 2026 first quarter conference call. My name is Clint Tomlinson. I will be your host for today's call. At this time, all participants are in a listen-only mode. Later, we will conduct a question and answer session. During the session, if you would like to ask a question, please use the Q&A box or raise your hand. Please note this conference is being recorded, and the call will be available on Anavex's website at www.anavex.com. With us today is Dr. Christopher Missling, President and Chief Executive Officer, and Sandra Boenisch, Principal Financial Officer. Before we begin, please note that during this conference call, the company will make some projections and forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. We encourage you to review the company's filings with the SEC, including, without limitation, the company's forms 10-K and 10-Q, to identify the specific factors that may cause actual results or events to differ materially from those described in these forward-looking statements. These factors may include, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, the need and ability to obtain future capital, and maintenance of intellectual property rights. This conference call discusses investigational uses of agents in development and is not intended to convey conclusions about efficacy or safety. There is no guarantee that any investigational uses of such products will successfully complete clinical development or gain health authority approval. And with that, I would like to turn the call over to Dr. Missling.
Christopher Missling CEO Thank you, Clint, and good morning, everyone. Thank you for being with us today to review our first quarter financial results and quarterly business update. As we enter 2026, we continue to progress our innovative clinical pipeline with a particular focus on our lead candidate, oral blarcamesine, in early Alzheimer's disease. Based on our commitment to improving the lives of patients with neurological disorders, we remain excited about the therapeutic potential of oral blarcamesine. We look forward to working with the regulatory agencies in Europe and in the U.S. to advance blarcamesine as a potential new treatment option for patients. We recently announced Anavex's participation as a key industry partner in Access AD, a major new European initiative designed to accelerate the adoption of innovative diagnostic and therapeutic approaches for Alzheimer's disease across real-world clinical settings.
Frequently Asked Questions About AVXL
When is Anavex Life Sciences's next earnings date?
Anavex Life Sciences's next earnings report is expected for Nov 23, 2026.
Did AVXL beat earnings estimates last quarter?
Yes. Anavex Life Sciences reported EPS of $0.08 for the quarter ended Jun 30, 2026, above the -$0.08 estimate, a 200.00% surprise.
What EPS do analysts expect from AVXL next quarter?
The consensus EPS estimate for Anavex Life Sciences for the quarter ended Sep 30, 2026 is -$0.11 from 3 analysts.
How often does AVXL beat earnings estimates?
Anavex Life Sciences beat the EPS estimate in 6 of the last 8 quarters, with an average surprise of +27.12%.
AVXL pages: Overview, Earnings, Forecast, Financials